Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis

Jewett, Anahid; Kos, Janko; Kaur, Kawaljit; Safaei, Tahmineh; Sutanto, Christine; Chen, Wuyang; Wong, Paul; Namagerdi, Artin Keshishian; Fang, Changge; Fong, Yuman; Ko, Meng-Wei

doi:10.1016/j.omto.2019.11.002

Cited by 55 publications

(64 citation statements)

References 100 publications

(192 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in a preclinical study with the B16 melanoma model, the Newcastle disease virus (NDV) activated T cells and NK cells, resulting in the induction of inflammatory responses, which led to lymphocyte infiltrates and an antitumor effect. 43 , 44 , 45 …”

Section: Discussionmentioning

confidence: 99%

Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma

Villa

Rahman

Mamola

et al. 2020

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematological malignancy of monoclonal plasma cells that remains incurable. Standard treatments for MM include myeloablative regimens and autologous cell transplantation for eligible patients. A major challenge of these treatments is the relapse of the disease due to residual MM in niches that become refractory to treatments. Therefore, novel therapies are needed in order to eliminate minimal residual disease (MRD). Recently, our laboratory reported that virotherapy with oncolytic myxoma virus (MYXV) improved MM-free survival in an allogeneic transplant mouse model. In this study, we demonstrate the capacity of donor autologous murine leukocytes, pre-armed with MYXV, to eliminate MRD in a BALB/c MM model. We report that MYXV-armed bone marrow (BM) carrier leukocytes are therapeutically superior to MYXV-armed peripheral blood mononuclear cells (PBMCs) or free virus. Importantly, when cured survivor mice were re-challenged with fresh myeloma cells, they developed immunity to the same MM that had comprised MRD. In vivo imaging demonstrated that autologous carrier cells armed with MYXV were very efficient at delivery of MYXV into the recipient tumor microenvironment. Finally, we demonstrate that treatment with MYXV activates the secretion of pro-immune molecules from the tumor bed. These results highlight the utility of exploiting autologous leukocytes to enhance tumor delivery of MYXV to treat MRD in vivo .

show abstract

Section: Discussionmentioning

confidence: 99%

Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma

Villa

Rahman

Mamola

et al. 2020

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

show abstract

“…Disease recurrence and metastasis are the fatal hallmark of cancer [1]. Several factors, such as cancer surgery, subsequent therapy and host immune function, affect risk of recurrence and metastasis [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Association between intraoperative administration of dexamethasone and survival after curative resection for non-small cell lung cancer (NSCLC): A propensity score matching analysis

Yan

Chen

Xie

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Few studies have suggested the correlation between intraoperative dexamethasone and oncological outcomes in non-small cell lung cancer (NSCLC) patients with radical resection. The existing data are inconsistent and inadequate, and more evidence is needed. We therefore undertook a propensity-matched cohort study to investigate the correlation.Methods: 832 patients with stage I to IIIa NSCLC who went through lung tumor resection between January 2008 and December 2013 were enrolled in our study. Propensity-score matching analysis created a population of 260 patients in the non-DEX group and 130 patients in the DEX group. Cox regression analyses were applied to compare the disease-free survival (DFS) and overall survival (OS) between patients who did not and did receive dexamethasone in the propensity score-matched cohort, as well as in the certain patients with high-risk factors of postoperative nausea and vomiting (PONV).Results: After propensity score matching, intraoperative dexamethasone was not significantly associated with DFS (HR: 0.944, 95%CI: 0.720-1.237, P = 0.655) and OS (HR: 1.210, 95%CI: 0.927-1.581, P = 0.486). Multivariable cox regression analysis revealed that intraoperative dexamethasone was not independent prognostic factor for DFS and OS in NSCLC patients undergoing surgical resection. In the subgroup analysis, including female subgroup, nonsmoking subgroup, long anesthetic time subgroup, VATS subgroup and inhaled anesthetics subgroup, intraoperative dexamethasone was not significantly associated with DFS and OS.Conclusion: There was no correlation between intraoperative administration of dexamethasone and survival in NSCLC patients after curative surgery. In the high-risk subgroups of PONV, that is, female, nonsmoking, long anesthetic time, VATS and inhaled anesthetics, patients given intraoperative dexamethasone had no better or poorer prognosis compared with patients not given intraoperative dexamethasone.

show abstract

“…Such a profile has also been extended to the immune responses of COVID-19 individuals. A study of 452 COVID-19 individuals demonstrated that the numbers of NK, B and T cells were significantly decreased, with more severe cases being associated with greater decreases in the numbers (15), Please see the references (16)(17)(18)(19) for reviews on the potential mechanisms of inactivation and loss of NK cells.…”

mentioning

confidence: 99%

“…The second key effector function of NK cells is the release of cytokines and chemokines. Two major cytokines released by NK cells are IFN-γ and TNF-α (16)(17)(18)(19)34). Released cytokines not only affect the function of innate and adaptive immune cells, but it can also impact the differentiation of both healthy and cancer cells (Figure 1).…”

mentioning

confidence: 99%

“…Indeed, NK cells are the army generals of the immune effectors which bring order and discipline to the infected tissue microenvironment. Without the NK cells it is likely that immune anarchy may ensue and result in the uncontrolled expansion and activation of other immune effectors ( 16 – 19 ). We have previously shown that NK cells also curtail the numbers of CD4+ T cells and expand CD8+ T cells ( 23 , 24 ) and (manuscript submitted).…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions

Jewett¹

2020

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Coronavirus-induced disease-2019 (COVID-19) continues to cause significant morbidity and mortality worldwide. While studies on SARS-CoV-2 effects on immune cell function continue to progress, we know very little about the significance of depletion of key immune effectors by the virus in the mortality and morbidity of the disease. This commentary outlines what is the reported literature thus far on the effect of virus on NK cells known to kill virally infected cells. It also underscores the necessity for the future comprehensive studies of NK cells in SARS-CoV-2 infected individuals and animal models to better understand the role and significance of reported NK cell depletion and functional inactivation in disease morbidity and mortality, in hope to design effective therapeutic interventions for the disease.

show abstract

Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis

Cited by 55 publications

References 100 publications

Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma

Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma

Association between intraoperative administration of dexamethasone and survival after curative resection for non-small cell lung cancer (NSCLC): A propensity score matching analysis

The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions

Contact Info

Product

Resources

About